USA - NASDAQ:CRON - CA22717L1013 - Common Stock
CRON gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. While CRON has a great health rating, there are worries on its profitability. While showing a medium growth rate, CRON is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 1.57% | ||
ROE | 1.71% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | 14.19% | ||
GM | 32.74% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 8.76 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 24.65 | ||
Quick Ratio | 23.53 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 55.6 | ||
Fwd PE | 38.94 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
2.78
-0.19 (-6.4%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 55.6 | ||
Fwd PE | 38.94 | ||
P/S | 8.17 | ||
P/FCF | N/A | ||
P/OCF | 53.16 | ||
P/B | 0.98 | ||
P/tB | 1.06 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 1.57% | ||
ROE | 1.71% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | 14.19% | ||
GM | 32.74% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 224.14% | ||
Cap/Sales | 22.6% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 24.65 | ||
Quick Ratio | 23.53 | ||
Altman-Z | 8.76 |